As a humanized antibody acting against human epidermal growth factor receptor 2 (HER2), trastuzumab has been approved by the FDA to treat metastatic GC, gastroesophageal junction cancer, as well as breast cancer expressing HER2 at very high levels 6, 7, 8. Here, ERBB2 is linked to breast carcinoma.